-
Veyonda® is being developed as a transformative anti-cancer treatment (DARRT) in combination with radiotherapy to produce off-target responses known as an abscopal effect
-
Pre-clinical studies now confirming this effect
-
This confirmation comes a week before release of key interim DARRT-1 clinical data
Sydney, 21 August 2019: Noxopharm Limited (ASX: NOX) (‘Noxopharm’ or the ‘Company’) is pleased to provide an update on results from a series of key proof-of-principle experiments in mice that are exploring the interaction between Veyonda® and radiotherapy in a novel and potentially transformative treatment regimen known as DARRT (Direct and Abscopal Response to Radiotherapy).
For further information please download the attached PDF:
Download this document
